Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics said after the close of the market on Thursday that its second quarter revenues rose 41 percent year over year.

For the three months ended June 30, Interpace posted $5.5 million in revenues, up from $3.9 million in Q2 2017, and surpassing the consensus Wall Street estimate of $5.0 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.